2-benzyl-4-benzyloxymethylpyridazin-3(2H)-one

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 2-benzyl-4-benzyloxymethylpyridazin-3(2H)-one
• 英文别名: 2-Benzyl-4-(phenylmethoxymethyl)pyridazin-3-one；2-benzyl-4-(phenylmethoxymethyl)pyridazin-3-one
• 化学式: C₁₉H₁₈N₂O₂
• 分子量: 306.364
• InChiKey: YGYJQTZGZHQVCN-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.1
• 重原子数：
  23
• 可旋转键数：
  6
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.16
• 拓扑面积：
  41.9
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为产物：
  描述：

  3-呋喃甲醇 在 咪唑 、 食用色素红色105号 、 四丁基氟化铵 、 氧气 、 sodium hydride 、 N,N-二异丙基乙胺 作用下， 以 四氢呋喃 、 甲醇 、 N,N-二甲基甲酰胺 、 mineral oil 为溶剂， 反应 79.5h， 生成 2-benzyl-4-benzyloxymethylpyridazin-3(2H)-one
  参考文献：
  名称：

  New platelet aggregation inhibitors based on pyridazinone moiety

  摘要：

  New series of pyridazinone derivatives (4, 5 and 6) were synthesized in good yields following a synthetic strategy based on singlet oxygen oxidation of alkyl furans, in which a suitable beta(alpha)-substituted gamma-hydroxybutenolide (10 or 11) or a bicyclic lactone (12 or 13) was the key intermediate. The synthesized compounds were tested in vitro as antiplatelet agents and some of them (compounds 4b, 4d and 5b) exhibited potent inhibitory effects on collagen-induced platelet aggregation with IC50 values in the low mu M range. Studies performed with the most active compound of these series (4b) demonstrated its lack of activity as inhibitor of platelet aggregation induced by other agonists as thrombin, ionomycin or U-46619 suggesting a selective action on the biochemical mechanisms triggered by collagen in the platelets. (C) 2015 Elsevier Masson SAS. All rights reserved.

  DOI：

  10.1016/j.ejmech.2015.02.061

文献信息

• New platelet aggregation inhibitors based on pyridazinone moiety
  作者：Tamara Costas、María Carmen Costas-Lago、Noemí Vila、Pedro Besada、Ernesto Cano、Carmen Terán

  DOI：10.1016/j.ejmech.2015.02.061

  日期：2015.4

  New series of pyridazinone derivatives (4, 5 and 6) were synthesized in good yields following a synthetic strategy based on singlet oxygen oxidation of alkyl furans, in which a suitable beta(alpha)-substituted gamma-hydroxybutenolide (10 or 11) or a bicyclic lactone (12 or 13) was the key intermediate. The synthesized compounds were tested in vitro as antiplatelet agents and some of them (compounds 4b, 4d and 5b) exhibited potent inhibitory effects on collagen-induced platelet aggregation with IC50 values in the low mu M range. Studies performed with the most active compound of these series (4b) demonstrated its lack of activity as inhibitor of platelet aggregation induced by other agonists as thrombin, ionomycin or U-46619 suggesting a selective action on the biochemical mechanisms triggered by collagen in the platelets. (C) 2015 Elsevier Masson SAS. All rights reserved.